This paper reviews current treatments for renal cell carcinoma/cancer (RCC) with the
multikinase inhibitors (MKIs) sorafenib, sunitinib, lenvatinib and axitinib. Furthermore, it …

Simple Summary The accumulated evidence on the role of epigenetic markers of prognosis
in clear cell renal cell carcinoma (ccRCC) is reviewed, as well as state of the art on …

Objective Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney tumor
characterized by the highest mortality rate of the genitourinary cancers, and, therefore, new …

Background Clear cell renal cell carcinoma (ccRCC) is one of the most aggressive
urological malignancies. MicroRNAs (miRNAs) are post-transcriptional gene regulators in …

Background Renal cell carcinoma (RCC) is the most common kidney cancer and includes
several molecular and histological subtypes with different clinical characteristics. The …

Current gold standard diagnostic strategies are unable to accurately differentiate malignant
from benign small renal masses preoperatively; consequently, 20% of patients undergo …

Most transcription factors were for a long time considered as undruggable targets because
of the absence of binding pockets for direct targeting. HOXA9, implicated in acute myeloid …

Background and purpose Genetic generalized epilepsies (GGEs) encompass a group of
syndromes of mainly genetic causes, characterized by the involvement of both hemispheres …

Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cell cancer with the highest
mortality, infiltration, and metastasis rate, threatening human health. Despite oncogenic role …

Context The 5-yr survival of early-stage renal cell carcinoma (RCC) is approximately 93%,
but once metastasised, the 5-yr survival plummets to 12%, indicating that early RCC …